参考文献/References:
[1] Perros P,Zˇarkovic' M,Azzolini C,et al.PREGO(presentation of Graves' orbitopathy)study:changes in referral patterns to European Group On Graves' Orbitopathy(EUGOGO)centres over the period from 2000 to 2012[J].Br J Ophthalmol,2015,99(11):1531-1535.DOI:10.1136/bjophthalmol-2015-306733.
[2] Bartalena L,Baldeschi L,Dickinson A,et al.European Group on Graves' Orbitopathy(EUGOGO).Consensus statement of the European Group on Graves' Orbitopathy(EUGOGO)on management of GO[J].Eur J Endocrinol,2008,158(3):273-285.DOI:10.1530/EJE-07-0666.
[3] Bartalena L,Baldeschi L,Boboridis K,et al.The 2016 European Thyroid Association/Europea Group on Graves' Orbitopathy Guideline for the Management of Graves' Orbitopathy[J].Eur Thyroid J,2016,5(1):9-26.DOI:10.1159/000443828.
[4] Bartalena L,Kahaly GJ,Baldeschi L,et al.The 2021 European Group on Graves' orbitopathy(EUGOGO)clinical practice guidelines for the medical management of Graves' orbitopathy[J].Eur J Endocrinol,2021,185(4):G43-G67.DOI:10.1530/EJE-21-0479.
[5] Jain AP,Gellada N,Ugradar S,et al.Teprotumumab reduces extraocular muscle and orbital fat volume in thyroid eye disease[J].Br J Ophthalmol,2022,106(2):165-171.DOI:10.1136/bjophthalmol-2020-317806.
[6] Sabini E,Mazzi B,Profilo MA,et al.High serum cholesterol is a novel risk factor for Graves' orbitopathy:results of a cross-sectional study[J].Thyroid,2018,28(3):386-394.DOI:10.1089/thy.2017.0430.
[7] Naselli A,Moretti D,Regalbuto C,et al.Evidence that baseline levels of low-density lipoproteins cholesterol affect the clinical response of Graves' ophthalmopathy to parenteral corticosteroids[J].Front Endocrinol(lausanne),2020,11:609895.DOI:10.3389/fendo.2020.609895.
[8] Nilsson A,Tsoumani K,Planck T.Statins decrease the risk of orbitopathy in newly diagnosed patients with Graves disease[J].J Clin Endocrinol Metab,2021,106(5):1325-1332.DOI:10.1210/clinem/dgab070.
[9] Ye X,Bo X,Hu X,et al.Efficacy and safety of mycophenolate mofetil in patients with active moderate-to-severe Graves' orbitopathy[J].Clin Endocrinol(Oxf),2017,86(2):247-255.DOI:10.1111/cen.13170.
[10] Kahaly GJ,Riedl M,König J,et al.Mycophenolate plus methylprednisolone versus methylprednisolone alone in active,moderate-to-severe Graves' orbitopathy(MINGO):a randomised,observer-masked,multicentre trial[J].Lancet Diabetes Endocrinol,2018,6(4):287-298.DOI:10.1016/S2213-8587(18)30020-2.
[11] Riedl M,Kolbe E,Kampmann E,et al.Prospectively recorded and MedDRA-coded safety data of intravenous methylprednisolone therapy in Graves' orbitopathy[J].J Endocrinol Invest,2015,38(2):177-182.DOI:10.1007/s40618-014-0227-x.
[12] Salvi M,Vannucchi G,Currò N,et al.Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy:a randomized controlled study[J].J Clin Endocrinol Metab,2015,100(2):422-431.DOI:10.1210/jc.2014-3014.
[13] Slentz DH,Nelson CC,Smith TJ.Teprotumumab:a novel therapeutic monoclonal antibody for thyroid-associated ophthalmopathy[J].Expert Opin Investig Drugs,2020,29(7):645-649.DOI:10.1080/13543784.2020.1772752.
[14] Kahaly GJ,Douglas RS,Holt RJ,et al.Teprotumumab for patients with active thyroid eye disease:a pooled data analysis,subgroup analyses,and off-treatment follow-up results from two randomised,double-masked,placebo-controlled,multicentre trials[J].Lancet Diabetes Endocrinol,2021,9(6):360-372.DOI:10.1016/S2213-8587(21)00056-5.
[15] Douglas RS,Kahaly GJ,Patel A,et al.Teprotumumab for the treatment of active thyroid eye disease[J].N Engl J Med,2020,382(4):341-352.DOI:10.1056/NEJMoa1910434.
[16] Smith TJ,Kahaly GJ,Ezra DG,et al.Teprotumumab for thyroid-associated ophthalmopathy[J].N Engl J Med,2017,376(18):1748-1761.DOI:10.1056/NEJMoa1614949.
[17] Pérez-Moreiras JV,Varela-Agra M,Prada-Sánchez MC,et al.Steroid-resistant graves' orbitopathy treated with tocilizumab in real-world clinical practice:a 9-year single-center experience[J].J Clin Med,2021,10(4):706.DOI:10.3390/jcm10040706.
[18] Sánchez-Bilbao L,Martínez-López D,Revenga M,et al.Anti-Ⅱ-6 receptor tocilizumab in refractory Graves' orbitopathy:national multicenter observational study of 48 patients[J].J Clin Med,2020,9(9):2816.DOI:10.3390/jcm9092816.
[19] Perez-Moreiras JV,Gomez-Reino JJ,Maneiro JR,et al.Tocilizumab in Graves orbitopathy study group.Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant Graves orbitopathy:a randomized clinical trial[J].Am J Ophthalmol,2018,195:181-190.DOI:10.1016/j.ajo.2018.07.038.
[20] Hamed Azzam S,Kang S,Salvi M,et al.Tocilizumab for thyroid eye disease[J].Cochrane Database Syst Rev,2018,11(11):CD012984.DOI:10.1002/14651858.CD012984.pub2.
[21] Lee SJ,Rim TH,Jang SY,et al.Treatment of upper eyelid retraction related to thyroid-associated ophthalmopathy using subconjunctival triamcinolone injections[J].Graefes Arch Clin Exp Ophthalmol,2013,251(1):261-270.DOI:10.1007/s00417-012-2153-y.
[22] Huebert I,Heinicke N,Kook D,et al.Dual platelet inhibition in cases of severe retrobulbar hemorrhage following retrobulbar and peribulbar anesthesia[J].J Cataract Refract Surg,2015,41(10):2092-2101.DOI:10.1016/j.jcrs.2015.10.051.
[23] Muller I,Cannavaro D,Dazzi D,et al.SARS-CoV-2-related atypical thyroiditis[J].Lancet Diabetes Endocrinol,2020,8(9):739-741.DOI:10.1016/S2213-8587(20)30266-7.
[24] Mizuno S,Inaba H,Kobayashi KI,et al.A case of postpartum thyroiditis following SARS-CoV-2 infection[J].Endocr J,2021,68(3):371-374.DOI:10.1507/endocrj.EJ20-0553.
[25] Vera-Lastra O,Ordinola Navarro A,Cruz Domiguez MP,et al.Two cases of Graves' disease following SARS-CoV-2 vaccination:an autoimmune/inflammatory syndrome induced by adjuvants[J].Thyroid,2021,31(9):1436-1439.DOI:10.1089/thy.2021.0142.
[26] Iremli BG,�瘙塁endur SN,Ünlütürk U.Three cases of subacute thyroiditis following SARS-CoV-2 vaccine:postvaccination ASIA syndrome[J].J Clin Endocrinol Metab,2021,106(9):2600-2605.DOI:10.1210/clinem/dgab373.
[27] Bartalena L,Chiovato L,Marcocci C,et al.Management of Graves' hyperthyroidism and orbitopathy in time of COVID-19 pandemic[J].J Endocrinol Invest,2020,43(8):1149-1151.DOI:10.1007/s40618-020-01293-7.
[28] Neumann S,Krieger CC,Gershengorn MC.Targeting TSH and IGF-1 receptors to treat thyroid eye disease[J].Eur Thyroid J,2020,9(Suppl 1):59-65.DOI:10.1159/000511538.
[29] Krause G,Eckstein A,Schülein R.Modulating TSH receptor signaling for therapeutic benefit[J].Eur Thyroid J,2020,9(Suppl 1):66-77.DOI:10.1159/000511871.
[30] Masetti G,Ludgate M.Microbiome and Graves' orbitopathy[J].Eur Thyroid J,2020,9(Suppl 1):78-85.DOI:10.1159/000512255.
相似文献/References:
[1]孟淑华,魏军平.TSHR信号转导通路在Graves眼病发病机制中的作用[J].国际内分泌代谢杂志,2014,(02):84.[doi:10.3760/cma.j.issn.1673-4157.2014.02.004]
Meng Shuhua,Wei Junping..Roles of TSHR signal transduction pathway in Graves' ophthalmopathy[J].International Journal of Endocrinology and Metabolism,2014,(04):84.[doi:10.3760/cma.j.issn.1673-4157.2014.02.004]
[2]孙红爽,乜春城,朱小丽,等.11β-HSD1在糖皮质激素联合高脂喂养
大鼠胰岛素抵抗中的作用[J].国际内分泌代谢杂志,2016,36(01):14.[doi:10.3760/cma.j.issn.1673-4157.2016.01.004]
Sun Hongshuang*,Nie Chuncheng,Zhu Xiaoli,et al.Effects of 11β-hydroxysteroid dehydrogenase type 1 on insulin resistance in rats induced by glucocorticoid and high fat diet[J].International Journal of Endocrinology and Metabolism,2016,36(04):14.[doi:10.3760/cma.j.issn.1673-4157.2016.01.004]
[3]曹琳 郑仁东 曹雯 许娟 孙洪平 刘超.甲状腺相关性眼病治疗新进展[J].国际内分泌代谢杂志,2019,39(01):25.[doi:10.3760/cma.j.issn.1673-4157.2019.01.006]
Cao Lin,Zheng Rendong,Cao Wen,et al.Update on the management of thyroid-associated ophthalmopathy[J].International Journal of Endocrinology and Metabolism,2019,39(04):25.[doi:10.3760/cma.j.issn.1673-4157.2019.01.006]
[4]陆晨雅,陈国芳,徐书杭,等.甲状腺相关性眼病处理的新视角:局部注射疗法[J].国际内分泌代谢杂志,2023,43(02):104.[doi:10.3760/cma.j.cn121383-20210426-04068
]
Lu Chenya,Chen Guofang,Xu Shuhang,et al.Therapy insight: local injections for the treatment of thyroid associated ophthalmopathy[J].International Journal of Endocrinology and Metabolism,2023,43(04):104.[doi:10.3760/cma.j.cn121383-20210426-04068
]
[5]郭伟红,何庆.21-羟化酶缺陷症的围妊娠期管理研究进展[J].国际内分泌代谢杂志,2023,43(02):128.[doi:10.3760/cma.j.cn121383-20211202-12006]
Guo Weihong,He Qing..Peripregnancy management of 21-hydroxylase deficiency[J].International Journal of Endocrinology and Metabolism,2023,43(04):128.[doi:10.3760/cma.j.cn121383-20211202-12006]
[6]谭婕 徐书杭.IL-6受体及其受体抗体在Graves眼病中的作用研究进展[J].国际内分泌代谢杂志,2023,43(05):380.[doi:10.3760/cma.j.cn121383-20220731-07068]
Tan Jie,Xu Shuhang..Update of interleukin-6 receptor and its antibody's role in Graves' orbitopathy[J].International Journal of Endocrinology and Metabolism,2023,43(04):380.[doi:10.3760/cma.j.cn121383-20220731-07068]